[go: up one dir, main page]

ES2042625T3 - Uso de una prostaglandina en combinacion con un agente bloqueante adrenergico para la reduccion de presion intraocular. - Google Patents

Uso de una prostaglandina en combinacion con un agente bloqueante adrenergico para la reduccion de presion intraocular.

Info

Publication number
ES2042625T3
ES2042625T3 ES88104999T ES88104999T ES2042625T3 ES 2042625 T3 ES2042625 T3 ES 2042625T3 ES 88104999 T ES88104999 T ES 88104999T ES 88104999 T ES88104999 T ES 88104999T ES 2042625 T3 ES2042625 T3 ES 2042625T3
Authority
ES
Spain
Prior art keywords
intraocular pressure
blocking agent
adrenergic blocking
eye
prostaglandine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88104999T
Other languages
English (en)
Other versions
ES2042625T5 (es
Inventor
Laszlo Z Bito
Johan Wilhelm Stjernschantz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Columbia University in the City of New York
Original Assignee
Pharmacia AB
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21876714&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2042625(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia AB, Columbia University in the City of New York filed Critical Pharmacia AB
Application granted granted Critical
Publication of ES2042625T3 publication Critical patent/ES2042625T3/es
Publication of ES2042625T5 publication Critical patent/ES2042625T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ESTA INVENCION PROPORCIONA UN METODO PARA TRATAR LA HIPERTENSION OCULAS O EL GLAUCOMA EN EL OJO DE UN SUJETO. EL METODO COMPRENDE PONER EN CONTACTO LA SUPERFICIE DEL OJO CON UNA CANTIDAD EFECTIVA COMO REDUCTORA DE LA PRESION INTRAOCULAR DE UNA MEZCLA DE UN AGENTE BLOQUEANTE ADRENERGICO Y UNA PROSTAGLANDINA O UN DERIVADO DE ELLA EN UN VEHICULO OFTALMOLOGICAMENTE COMPATIBLE, DE FORMA QUE SE REDUZCA LA PRESION INTRAOCULAR DEL OJO Y LA MANTENGA REDUCIDA. ESTA INVENCION PRESENTA TAMBIEN UNA COMPOSICION PARA EL TRATAMIENTO DE LA HIPERTENSION OCULAR O DEL GLAUCOMA EN EL OJO DE UN SUJETO. LA COMPOSICION CONTIENE UNA CANTIDAD EFECTIVA COMO REDUCTORA DE LA PRESION INTRAOCULAR DE UNA MEZCLA DE UN AGENTE BLANQUEANTE ADRENERGICO Y UNA PROSTAGLANDINA O UN DERIVADO DE ESTA EN UN VEHICULO OFTALMOLOGICAMENTE COMPATIBLE.
ES88104999T 1987-04-03 1988-03-28 Uso de una prostaglandina en combinacion con un agente bloqueante adrenergico para la reduccion de presion intraocular. Expired - Lifetime ES2042625T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3448487A 1987-04-03 1987-04-03

Publications (2)

Publication Number Publication Date
ES2042625T3 true ES2042625T3 (es) 1993-12-16
ES2042625T5 ES2042625T5 (es) 2000-07-16

Family

ID=21876714

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88104999T Expired - Lifetime ES2042625T5 (es) 1987-04-03 1988-03-28 Uso de una prostaglandina en combinacion con un agente bloqueante adrenergico para la reduccion de presion intraocular.

Country Status (9)

Country Link
EP (1) EP0286903B2 (es)
JP (1) JP2726672B2 (es)
AT (1) ATE76750T1 (es)
AU (1) AU607981B2 (es)
CA (1) CA1314220C (es)
DE (1) DE3871596T3 (es)
ES (1) ES2042625T5 (es)
GR (2) GR3004794T3 (es)
HU (1) HU211835A9 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334168C (en) * 1988-04-26 1995-01-31 Louis M. De Santis Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers
US5173507A (en) * 1988-07-18 1992-12-22 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
CA2021316C (en) * 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US5198545A (en) * 1989-11-13 1993-03-30 Allergan, Inc. Pharmaceutical epinephrine-pilocarpine compounds and process of preparation thereof
US5055467A (en) * 1989-11-13 1991-10-08 Allergan, Inc. Pharmaceutical epinephrine-pilocarpine compounds
US5011856A (en) * 1990-03-12 1991-04-30 Allergan, Inc. Use of prostaglandin F3 α as an ocular hypotensive agent
CA2042934C (en) * 1990-05-22 2002-04-23 Ryuji Ueno Treatment of ocular hypertension with an ocular synergistic combination
CA2042937C (en) * 1990-05-22 2002-04-30 Ryuji Ueno Treatment of ocular hypertension with a synergistic combination
DK0458587T3 (da) * 1990-05-22 1993-08-23 R Tech Ueno Ltd Behandling af okulær hypertension med en synergistisk kombination til ophthalmisk anvendelse
US5238961A (en) * 1990-06-14 1993-08-24 Allergan, Inc. Pgf 1-alcohols and their use as ocular hypotensives
TW210287B (es) * 1991-03-01 1993-08-01 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo
ATE207360T1 (de) * 1992-03-19 2001-11-15 R Tech Ueno Ltd Behandlung von augenhochdruck mit betablockern und prostansäurederivaten
JPH06107547A (ja) * 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk 眼科用組成物
ES2105333T3 (es) * 1992-10-13 1997-10-16 Alcon Lab Inc Combinaciones de prostaglandinas y derivados de clonidina para el tratamiento del glaucoma.
US5574066A (en) * 1992-10-28 1996-11-12 Allergan Intraocular pressure reducing 15-acyl prostaglandins
SE9402816D0 (sv) * 1994-08-24 1994-08-24 Pharmacia Ab Method and meams for drug administration
US5698733A (en) * 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
AU746893B2 (en) * 1998-01-23 2002-05-02 Merck Sharp & Dohme B.V. Method for increasing oxygen tension in the optic nerve and retina
EP1386611A4 (en) * 2001-04-19 2009-05-13 Teika Pharmaceutical Co Ltd MEDICAL DEVICES AND MEDICAL SETS
TWI298257B (en) * 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
AU2007200821A1 (en) * 2001-05-31 2007-03-15 Allergan, Inc. Hypotensive lipid and timolol compositions and methods of using same
TW200305424A (en) 2002-01-29 2003-11-01 Santen Pharmaceutical Co Ltd Glaucoma-treating agent comprising bunazosin and prostaglandin
WO2004019951A1 (ja) * 2002-08-29 2004-03-11 Santen Pharmaceutical Co., Ltd. Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
AU2003280812A1 (en) 2002-11-18 2004-06-15 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND Beta-BLOCKER
US7186744B2 (en) * 2003-11-13 2007-03-06 Allergan, Inc. Prostamides for the treatment of glaucoma and related diseases
KR101333990B1 (ko) 2005-07-12 2013-11-27 코와 가부시키가이샤 녹내장을 예방 또는 치료하는 약제
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
US20120184552A1 (en) * 2009-09-17 2012-07-19 Senju Pharmaceutical Co., Ltd. Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin
US9078854B2 (en) 2010-07-29 2015-07-14 Allergan, Inc. Preservative free bimatoprost and timolol solutions
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
CN103338772A (zh) 2011-02-04 2013-10-02 兴和株式会社 用于预防或治疗青光眼的药物疗法
WO2014010654A2 (ja) * 2012-07-13 2014-01-16 参天製薬株式会社 スルホンアミド化合物の組み合わせ
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
WO2019124488A1 (ja) 2017-12-21 2019-06-27 参天製薬株式会社 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬
WO2019124487A1 (ja) 2017-12-21 2019-06-27 参天製薬株式会社 オミデネパグの組合せ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454154A (en) * 1981-06-23 1984-06-12 American Hospital Supply Corporation Method for treating glaucoma by the topical administration of selectively metabolized beta-blocking agents
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
DE3300933A1 (de) * 1983-01-13 1984-07-19 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von d,l- und d-carazolol als antiglaukommittel sowie arzneimittel, die diese stoffe enthalten
ES2053458T3 (es) * 1986-03-13 1994-08-01 Univ Columbia Utilizacion de prostaglandinas a, b y c y derivados de las mismas, para el tratamiento de la hipertension ocular y glaucoma.

Also Published As

Publication number Publication date
EP0286903A1 (en) 1988-10-19
DE3871596D1 (de) 1992-07-09
DE3871596T2 (de) 1993-01-21
CA1314220C (en) 1993-03-09
GR3033721T3 (en) 2000-10-31
HU211835A9 (en) 1995-12-28
AU1387088A (en) 1988-10-06
ATE76750T1 (de) 1992-06-15
GR3004794T3 (es) 1993-04-28
DE3871596T3 (de) 2000-09-07
JP2726672B2 (ja) 1998-03-11
ES2042625T5 (es) 2000-07-16
EP0286903B1 (en) 1992-06-03
AU607981B2 (en) 1991-03-21
EP0286903B2 (en) 2000-03-29
JPS63313728A (ja) 1988-12-21

Similar Documents

Publication Publication Date Title
ES2042625T5 (es) Uso de una prostaglandina en combinacion con un agente bloqueante adrenergico para la reduccion de presion intraocular.
ES2053458T3 (es) Utilizacion de prostaglandinas a, b y c y derivados de las mismas, para el tratamiento de la hipertension ocular y glaucoma.
MX9702349A (es) Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma.
ES2062102T3 (es) Derivados de prostaglandinas para el tratamiento de glaucoma o hipertension ocular.
PT868186E (pt) Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular
IE811654L (en) Ophthalmic composition
DE3872701D1 (de) Prostaglandin-derivate zur behandlung von glaucoma oder augenueberdruck.
PT89307A (pt) Aplicador de infusao e processo de preparacao de composicoes a base de (mono)oxicloroseno ou de oxicloroseno de sodio para o mesmo
EP0363469A4 (en) Lacrimal secretion stimulant (lss)
FI911131A0 (fi) Menetelmä viherkaihia estävien 3-aryylikarbonyyli-1-aminoalkyyli-1H-indoliyhdisteiden valmistamiseksi
ES2141736T3 (es) Gel, especialmente para uso terapeutico ocular.
ATE117208T1 (de) Behandlung von intraokularem druck mit einer ophthalmischen synergistischen kombination.
DE69116224D1 (de) Behandlung von intraokularem Druck mit einer synergischen Kombination
DE69320329D1 (de) Topische Antiglaukoma Zusammensetzungen, enthaltend Karbonhydrasehemmer und Beta-Blocker
DE69829062D1 (de) Verwendung von flunarizin zur topischen behandlung ocularem hochdruck
ATE133337T1 (de) Behandlung des glaukoms mit synergistischer kombination
ES2170807T3 (es) Uso de prostaglandinas para la fabricacion de un medicamento para la prevencion y el tratamiento de catarata secundaria.
HU9301364D0 (en) Homo-prostaglandines applicables for treatment of hypertension in eyes
WO1998001099A3 (en) Method of treating retinal ischemia and glaucoma
ES2088489T3 (es) Uso de prostaglandina f3alfa como agente ocular hipotensivo.
CO4340602A1 (es) Estructura perfeccionada para gafas protectoras
JO1317B1 (en) Eye treatment
NO923642L (no) Anvendelse av 5-trans-prostaglandin f2alfa som et okulart hypotensivt middel
IT1241928B (it) Composizione oftalmica per l'uso nel mantenimento della midriasi oculare

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 286903

Country of ref document: ES